A hospital can qualify for a federal drug discount program based on the patients it serves, yet the financial benefits don't necessarily flow to the hospitals caring for the greatest number of patients in need.
That's one of the concerns raised by Dr. Anthony DiGiorgio, a neurosurgeon at UC San Francisco, during a discussion about the 340B program at the State of the Patient Summit.
The conversation explored how hospitals generate revenue from discounted medications, why some health systems benefit more than others and what proposed reforms could mean for patients.
Hear what Dr. DiGiorgio and fellow panelists had to say in the latest episode of the State of the Patient podcast.
Listen to the episode: